Both in Pharmaceuticals
Akebia Therapeutics vs Niagen Bioscience
Over the past year AKBA returned −65.8% and NAGE returned −64.5%; their daily moves had a correlation of 0.22.
AKBA −65.8% NAGE −64.5%Growth of $1, one year, split-adjusted
| Metric | AKBA | NAGE |
|---|---|---|
| Price | $0.7252 | $2.57 |
| Market cap | $201.0M | $203.4M |
| Today | −0.08% | +8.90% |
| 1 month | −17.5% | −4.5% |
| 6 months | −51.0% | −48.3% |
| Year to date | −55.0% | −59.6% |
| 1 year | −65.8% | −64.5% |
| Revenue growth (YoY) | −21.4% | −4.3% |
| Gross margin | 78.8% | 64.8% |
| Net margin | −18.1% | 3.2% |
| P/E (TTM) | — | 12.7× |
| Price / sales | 0.9× | 1.6× |
| Net cash | $106.0M | $66.7M |
| Dividend yield | — | — |
| Volatility (60d) | 71.8% | 41.3% |
| Short % of float | 8.7% | 8.0% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).